Change over period: —
NSE · INDSWFTLAB
IND-SWIFT LA
-18.5% from the 52-week high · +282.0% above the low
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm is in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates, and formulations. The firm operates one business segment viz. Bulk Drugs and Pharmaceuticals. The company offers three products or services, which includes APIs, Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The company has two manufacturing facilities and one Research Centre. Its API business caters to the needs of the regulated markets, including USA, Europe, Korea, Japan and Latin America. Its research and development (R&D) center is primarily focused on the development and optimization of new and existing process technologies supporting the manufacturing of APIs. Its products under API include Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, Parkinson’s Disease, Hyperparathyroidism, Analgesic (Controlled Substances), and Aromatase Inhibitor.
The short version. IND-SWIFT LA reported revenue of ₹240 crore for Sep 2026, up 56.9% from a year earlier. Net profit was ₹34 crore (up 325.0% year on year). Return on equity was 3.0% in Mar 2026. Promoter holding was 42.93% in Sep 2026, up 0.93 points over 8 quarters.
1 · The price
How has the stock traded?
IND-SWIFT LA trades 18.5% below its 52-week high and 282.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹240 cr.
Sep 2026 net profit of ₹34 cr.
9.0 pts higher than a year earlier.
Revenue compounded at -17.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 240 | 191 | 170 | 151 | 153 | 153 | 138 | 9 |
| Net profit | 34 | 25 | 15 | 10 | 8 | 9 | 222 | 0 |
| Net margin % | 14.2 | 12.9 | 8.9 | 6.3 | 5.2 | 5.7 | 160.8 | 0.1 |
| EPS (₹) | 3.94 | 2.84 | 1.74 | 1.17 | 0.98 | 1.45 | 36.67 | 0.0 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 641 | 562 | 1281 | 1207 | 1039 | 891 | 780 | 757 |
| Net profit | 41 | 250 | 421 | 48 | -2 | -3 | -21 | 38 |
| Net margin % | 6.5 | 44.6 | 32.9 | 3.9 | -0.2 | -0.4 | -2.7 | 5.1 |
| EPS (₹) | 4.77 | 41.32 | 71.33 | 8.06 | -0.36 | -0.53 | -3.59 | 8.08 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 3.0% in Mar 2026; debt to equity is 0.01.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 3.0 | 21.3 | 45.2 | 7.0 |
| Return on capital % | 3.6 | 21.4 | 67.0 | 12.3 |
| EBITDA margin % | 11.8 | 44.4 | 51.7 | 19.0 |
| Net margin % | 6.0 | 39.0 | 31.8 | 3.8 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -17.8% | -5.5% |
| Profit CAGR | -4.5% | — |
4 · The owners
Who holds it, and are they adding?
Up 0.93 pts over 8 quarters.
Up 10.32 pts over 8 quarters.
Down 0.74 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 42.0 | 40.94 | 40.94 | 39.5 | 39.5 | 42.99 | 42.93 | 42.93 | +0.93 |
| FII | 0.46 | 3.07 | 4.27 | 14.8 | 14.33 | 13.88 | 10.7 | 10.78 | +10.32 |
| DII | 0.94 | 0.91 | 0.91 | 0.68 | 0.68 | 0 | 0.17 | 0.2 | -0.74 |
| Public | 56.6 | 55.07 | 53.87 | 45.02 | 45.5 | 43.12 | 46.2 | 46.09 | -10.51 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.11% of NAV
- Bandhan BSE Healthcare Index Fund0.11% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for IND-SWIFT LA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about IND-SWIFT LA
What is the IND-SWIFT LA share price?
IND-SWIFT LA (INDSWFTLAB) last closed at ₹330.25, down 1.93% on the day. Its 52-week range is ₹88.15 to ₹413.10.
What is the market cap of IND-SWIFT LA?
IND-SWIFT LA has a market capitalisation of about ₹2,921 crore. Its price-to-earnings ratio is 34.8.
How are IND-SWIFT LA's latest results?
IND-SWIFT LA reported revenue of ₹240 crore for Sep 2026, up 56.9% from a year earlier. Net profit was ₹34 crore (up 325.0% year on year). Return on equity was 3.0% in Mar 2026. Promoter holding was 42.93% in Sep 2026, up 0.93 points over 8 quarters.
Who owns IND-SWIFT LA?
As of Sep 2026, shareholding was: Promoter 42.93%, FII 10.78%, DII 0.2%, Public 46.09%.
How many mutual funds hold IND-SWIFT LA?
2 mutual fund schemes held IND-SWIFT LA in October 2026. That compares with 2 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.